Lilly and Hims & Hers expand access to FDA-approved Lilly medicines
Article excerpt
Highlighted: the sentence this signal was extracted from
Agreement gives patients a path to FDA-approved treatments at self-pay price through the Hims & Hers platform INDIANAPOLIS, Nov. 6, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Hims & Hers Health, Inc. (NYSE: HIMS ) today announced an agreement to help expand access to Zepbound (tirzepatide) and Foundayo (orforglipron). Through the agreement, eligible patients who receive a prescription from a licensed provider on the Hims & Hers platform will access the same self-pay prices available to any patient without leaving the Hims & Hers platform. The agreement brings together Lilly's obesity medicines and Hims & Hers' consumer platform. Patients can complete a consultation, receive a prescription if their provider determines it is appropriate, and have an FDA-approved Lilly medicine shipped directly to their home, all in one seamless experience. Self-pay pricing starts at $149 per month for Foundayo and $299 per month for Zepbound. "At Lilly, we are always looking for new ways to help more people get the medicines they need, and that means meeting patients where they already are," said Ilya Yuffa, Executive Vice President and President, Lilly USA and Global Customer Capabilities, Eli Lilly and Company. "Millions of people turn to Hims & Hers for their care, and through this agreement, those patients now have a simple, more direct way to get FDA-approved Lilly...
Keep reading with a free account
The rest of this article, and every signal for Eli Lilly, is in your free account.
